List of Tables
Table 1. Rare Neurodegenerative Disease Treatment Market Trends
Table 2. Rare Neurodegenerative Disease Treatment Market Drivers & Opportunity
Table 3. Rare Neurodegenerative Disease Treatment Market Challenges
Table 4. Rare Neurodegenerative Disease Treatment Market Restraints
Table 5. Global Rare Neurodegenerative Disease Treatment Revenue by Company (2019-2024) & (US$ Million)
Table 6. Global Rare Neurodegenerative Disease Treatment Revenue Market Share by Company (2019-2024)
Table 7. Global Rare Neurodegenerative Disease Treatment Sales Volume by Company (2019-2024) & (K Units)
Table 8. Global Rare Neurodegenerative Disease Treatment Sales Volume Market Share by Company (2019-2024)
Table 9. Global Market Rare Neurodegenerative Disease Treatment Price by Company (2019-2024) & (US$/Unit)
Table 10. Key Manufacturers Rare Neurodegenerative Disease Treatment Manufacturing Base Distribution and Headquarters
Table 11. Key Manufacturers Rare Neurodegenerative Disease Treatment Product Type
Table 12. Key Manufacturers Time to Begin Mass Production of Rare Neurodegenerative Disease Treatment
Table 13. Global Rare Neurodegenerative Disease Treatment Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Top Manufacturers Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Rare Neurodegenerative Disease Treatment as of 2023)
Table 15. Mergers & Acquisitions, Expansion Plans
Table 16. Global Rare Neurodegenerative Disease Treatment Sales Value by Type: 2019 VS 2023 VS 2030 (US$ Million)
Table 17. Global Rare Neurodegenerative Disease Treatment Sales Value by Type (2019-2024) & (US$ Million)
Table 18. Global Rare Neurodegenerative Disease Treatment Sales Value by Type (2025-2030) & (US$ Million)
Table 19. Global Rare Neurodegenerative Disease Treatment Sales Market Share in Value by Type (2019-2024) & (%)
Table 20. Global Rare Neurodegenerative Disease Treatment Sales Market Share in Value by Type (2025-2030) & (%)
Table 21. Global Rare Neurodegenerative Disease Treatment Sales Volume by Type: 2019 VS 2023 VS 2030 (K Units)
Table 22. Global Rare Neurodegenerative Disease Treatment Sales Volume by Type (2019-2024) & (K Units)
Table 23. Global Rare Neurodegenerative Disease Treatment Sales Volume by Type (2025-2030) & (K Units)
Table 24. Global Rare Neurodegenerative Disease Treatment Sales Market Share in Volume by Type (2019-2024) & (%)
Table 25. Global Rare Neurodegenerative Disease Treatment Sales Market Share in Volume by Type (2025-2030) & (%)
Table 26. Global Rare Neurodegenerative Disease Treatment Price by Type (2019-2024) & (US$/Unit)
Table 27. Global Rare Neurodegenerative Disease Treatment Price by Type (2025-2030) & (US$/Unit)
Table 28. Global Rare Neurodegenerative Disease Treatment Sales Value by Application: 2019 VS 2023 VS 2030 (US$ Million)
Table 29. Global Rare Neurodegenerative Disease Treatment Sales Value by Application (2019-2024) & (US$ Million)
Table 30. Global Rare Neurodegenerative Disease Treatment Sales Value by Application (2025-2030) & (US$ Million)
Table 31. Global Rare Neurodegenerative Disease Treatment Sales Market Share in Value by Application (2019-2024) & (%)
Table 32. Global Rare Neurodegenerative Disease Treatment Sales Market Share in Value by Application (2025-2030) & (%)
Table 33. Global Rare Neurodegenerative Disease Treatment Sales Volume by Application: 2019 VS 2023 VS 2030 (K Units)
Table 34. Global Rare Neurodegenerative Disease Treatment Sales Volume by Application (2019-2024) & (K Units)
Table 35. Global Rare Neurodegenerative Disease Treatment Sales Volume by Application (2025-2030) & (K Units)
Table 36. Global Rare Neurodegenerative Disease Treatment Sales Market Share in Volume by Application (2019-2024) & (%)
Table 37. Global Rare Neurodegenerative Disease Treatment Sales Market Share in Volume by Application (2025-2030) & (%)
Table 38. Global Rare Neurodegenerative Disease Treatment Price by Application (2019-2024) & (US$/Unit)
Table 39. Global Rare Neurodegenerative Disease Treatment Price by Application (2025-2030) & (US$/Unit)
Table 40. Global Rare Neurodegenerative Disease Treatment Sales Value by Region: 2019 VS 2023 VS 2030 (US$ Million)
Table 41. Global Rare Neurodegenerative Disease Treatment Sales Value by Region (2019-2024) & (US$ Million)
Table 42. Global Rare Neurodegenerative Disease Treatment Sales Value by Region (2025-2030) & (US$ Million)
Table 43. Global Rare Neurodegenerative Disease Treatment Sales Value by Region (2019-2024) & (%)
Table 44. Global Rare Neurodegenerative Disease Treatment Sales Value by Region (2025-2030) & (%)
Table 45. Global Rare Neurodegenerative Disease Treatment Sales Volume by Region (K Units): 2019 VS 2023 VS 2030
Table 46. Global Rare Neurodegenerative Disease Treatment Sales Volume by Region (2019-2024) & (K Units)
Table 47. Global Rare Neurodegenerative Disease Treatment Sales Volume by Region (2025-2030) & (K Units)
Table 48. Global Rare Neurodegenerative Disease Treatment Sales Volume by Region (2019-2024) & (%)
Table 49. Global Rare Neurodegenerative Disease Treatment Sales Volume by Region (2025-2030) & (%)
Table 50. Global Rare Neurodegenerative Disease Treatment Average Price by Region (2019-2024) & (US$/Unit)
Table 51. Global Rare Neurodegenerative Disease Treatment Average Price by Region (2025-2030) & (US$/Unit)
Table 52. Key Countries/Regions Rare Neurodegenerative Disease Treatment Sales Value Growth Trends, (US$ Million): 2019 VS 2023 VS 2030
Table 53. Key Countries/Regions Rare Neurodegenerative Disease Treatment Sales Value, (2019-2024) & (US$ Million)
Table 54. Key Countries/Regions Rare Neurodegenerative Disease Treatment Sales Value, (2025-2030) & (US$ Million)
Table 55. Key Countries/Regions Rare Neurodegenerative Disease Treatment Sales Volume, (2019-2024) & (K Units)
Table 56. Key Countries/Regions Rare Neurodegenerative Disease Treatment Sales Volume, (2025-2030) & (K Units)
Table 57. Bayer Company Information
Table 58. Bayer Introduction and Business Overview
Table 59. Bayer Rare Neurodegenerative Disease Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 60. Bayer Rare Neurodegenerative Disease Treatment Product Offerings
Table 61. Bayer Recent Development
Table 62. GlaxoSmithKline Company Information
Table 63. GlaxoSmithKline Introduction and Business Overview
Table 64. GlaxoSmithKline Rare Neurodegenerative Disease Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 65. GlaxoSmithKline Rare Neurodegenerative Disease Treatment Product Offerings
Table 66. GlaxoSmithKline Recent Development
Table 67. Hoffmann-La Roche Company Information
Table 68. Hoffmann-La Roche Introduction and Business Overview
Table 69. Hoffmann-La Roche Rare Neurodegenerative Disease Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 70. Hoffmann-La Roche Rare Neurodegenerative Disease Treatment Product Offerings
Table 71. Hoffmann-La Roche Recent Development
Table 72. Allergan Company Information
Table 73. Allergan Introduction and Business Overview
Table 74. Allergan Rare Neurodegenerative Disease Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 75. Allergan Rare Neurodegenerative Disease Treatment Product Offerings
Table 76. Allergan Recent Development
Table 77. Merck KGaA Company Information
Table 78. Merck KGaA Introduction and Business Overview
Table 79. Merck KGaA Rare Neurodegenerative Disease Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 80. Merck KGaA Rare Neurodegenerative Disease Treatment Product Offerings
Table 81. Merck KGaA Recent Development
Table 82. Johnson and Johnson Company Information
Table 83. Johnson and Johnson Introduction and Business Overview
Table 84. Johnson and Johnson Rare Neurodegenerative Disease Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 85. Johnson and Johnson Rare Neurodegenerative Disease Treatment Product Offerings
Table 86. Johnson and Johnson Recent Development
Table 87. Pfizer Company Information
Table 88. Pfizer Introduction and Business Overview
Table 89. Pfizer Rare Neurodegenerative Disease Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 90. Pfizer Rare Neurodegenerative Disease Treatment Product Offerings
Table 91. Pfizer Recent Development
Table 92. Novartis Company Information
Table 93. Novartis Introduction and Business Overview
Table 94. Novartis Rare Neurodegenerative Disease Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 95. Novartis Rare Neurodegenerative Disease Treatment Product Offerings
Table 96. Novartis Recent Development
Table 97. Sanofi Company Information
Table 98. Sanofi Introduction and Business Overview
Table 99. Sanofi Rare Neurodegenerative Disease Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 100. Sanofi Rare Neurodegenerative Disease Treatment Product Offerings
Table 101. Sanofi Recent Development
Table 102. Teva Pharmaceuticals Company Information
Table 103. Teva Pharmaceuticals Introduction and Business Overview
Table 104. Teva Pharmaceuticals Rare Neurodegenerative Disease Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 105. Teva Pharmaceuticals Rare Neurodegenerative Disease Treatment Product Offerings
Table 106. Teva Pharmaceuticals Recent Development
Table 107. Key Raw Materials Lists
Table 108. Raw Materials Key Suppliers Lists
Table 109. Rare Neurodegenerative Disease Treatment Downstream Customers
Table 110. Rare Neurodegenerative Disease Treatment Distributors List
Table 111. Research Programs/Design for This Report
Table 112. Key Data Information from Secondary Sources
Table 113. Key Data Information from Primary Sources
List of Figures
Figure 1. Rare Neurodegenerative Disease Treatment Product Picture
Figure 2. Global Rare Neurodegenerative Disease Treatment Sales Value, 2019 VS 2023 VS 2030 (US$ Million)
Figure 3. Global Rare Neurodegenerative Disease Treatment Sales Value (2019-2030) & (US$ Million)
Figure 4. Global Rare Neurodegenerative Disease Treatment Sales Volume (2019-2030) & (K Units)
Figure 5. Global Rare Neurodegenerative Disease Treatment Sales Price (2019-2030) & (US$/Unit)
Figure 6. Rare Neurodegenerative Disease Treatment Report Years Considered
Figure 7. Global Rare Neurodegenerative Disease Treatment Players Revenue Ranking (2023) & (US$ Million)
Figure 8. Global Rare Neurodegenerative Disease Treatment Players Sales Volume Ranking (2023) & (K Units)
Figure 9. The 5 and 10 Largest Manufacturers in the World: Market Share by Rare Neurodegenerative Disease Treatment Revenue in 2023
Figure 10. Rare Neurodegenerative Disease Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023
Figure 11. Neurotransmitter Agents Picture
Figure 12. Neuroprotective Agents Picture
Figure 13. Biologics Picture
Figure 14. Others Picture
Figure 15. Global Rare Neurodegenerative Disease Treatment Sales Value by Type (2019 VS 2023 VS 2030) & (US$ Million)
Figure 16. Global Rare Neurodegenerative Disease Treatment Sales Value Market Share by Type, 2023 & 2030
Figure 17. Global Rare Neurodegenerative Disease Treatment Sales Volume by Type (2019 VS 2023 VS 2030) & (K Units)
Figure 18. Global Rare Neurodegenerative Disease Treatment Sales Volume Market Share by Type, 2023 & 2030
Figure 19. Global Rare Neurodegenerative Disease Treatment Price by Type (2019-2030) & (US$/Unit)
Figure 20. Product Picture of Amyotrophic Lateral Sclerosis (ALS)
Figure 21. Product Picture of Attention Deficit Hyperactivity Disorder (ADHD)
Figure 22. Product Picture of Alzheimer’s Disease
Figure 23. Product Picture of Parkinson’s Disease
Figure 24. Product Picture of Others
Figure 25. Global Rare Neurodegenerative Disease Treatment Sales Value by Application (2019 VS 2023 VS 2030) & (US$ Million)
Figure 26. Global Rare Neurodegenerative Disease Treatment Sales Value Market Share by Application, 2023 & 2030
Figure 27. Global Rare Neurodegenerative Disease Treatment Sales Volume by Application (2019 VS 2023 VS 2030) & (K Units)
Figure 28. Global Rare Neurodegenerative Disease Treatment Sales Volume Market Share by Application, 2023 & 2030
Figure 29. Global Rare Neurodegenerative Disease Treatment Price by Application (2019-2030) & (US$/Unit)
Figure 30. North America Rare Neurodegenerative Disease Treatment Sales Value (2019-2030) & (US$ Million)
Figure 31. North America Rare Neurodegenerative Disease Treatment Sales Value by Country (%), 2023 VS 2030
Figure 32. Europe Rare Neurodegenerative Disease Treatment Sales Value (2019-2030) & (US$ Million)
Figure 33. Europe Rare Neurodegenerative Disease Treatment Sales Value by Country (%), 2023 VS 2030
Figure 34. Asia Pacific Rare Neurodegenerative Disease Treatment Sales Value (2019-2030) & (US$ Million)
Figure 35. Asia Pacific Rare Neurodegenerative Disease Treatment Sales Value by Country (%), 2023 VS 2030
Figure 36. South America Rare Neurodegenerative Disease Treatment Sales Value (2019-2030) & (US$ Million)
Figure 37. South America Rare Neurodegenerative Disease Treatment Sales Value by Country (%), 2023 VS 2030
Figure 38. Middle East & Africa Rare Neurodegenerative Disease Treatment Sales Value (2019-2030) & (US$ Million)
Figure 39. Middle East & Africa Rare Neurodegenerative Disease Treatment Sales Value by Country (%), 2023 VS 2030
Figure 40. Key Countries/Regions Rare Neurodegenerative Disease Treatment Sales Value (%), (2019-2030)
Figure 41. Key Countries/Regions Rare Neurodegenerative Disease Treatment Sales Volume (%), (2019-2030)
Figure 42. United States Rare Neurodegenerative Disease Treatment Sales Value, (2019-2030) & (US$ Million)
Figure 43. United States Rare Neurodegenerative Disease Treatment Sales Value by Type (%), 2023 VS 2030
Figure 44. United States Rare Neurodegenerative Disease Treatment Sales Value by Application (%), 2023 VS 2030
Figure 45. Europe Rare Neurodegenerative Disease Treatment Sales Value, (2019-2030) & (US$ Million)
Figure 46. Europe Rare Neurodegenerative Disease Treatment Sales Value by Type (%), 2023 VS 2030
Figure 47. Europe Rare Neurodegenerative Disease Treatment Sales Value by Application (%), 2023 VS 2030
Figure 48. China Rare Neurodegenerative Disease Treatment Sales Value, (2019-2030) & (US$ Million)
Figure 49. China Rare Neurodegenerative Disease Treatment Sales Value by Type (%), 2023 VS 2030
Figure 50. China Rare Neurodegenerative Disease Treatment Sales Value by Application (%), 2023 VS 2030
Figure 51. Japan Rare Neurodegenerative Disease Treatment Sales Value, (2019-2030) & (US$ Million)
Figure 52. Japan Rare Neurodegenerative Disease Treatment Sales Value by Type (%), 2023 VS 2030
Figure 53. Japan Rare Neurodegenerative Disease Treatment Sales Value by Application (%), 2023 VS 2030
Figure 54. South Korea Rare Neurodegenerative Disease Treatment Sales Value, (2019-2030) & (US$ Million)
Figure 55. South Korea Rare Neurodegenerative Disease Treatment Sales Value by Type (%), 2023 VS 2030
Figure 56. South Korea Rare Neurodegenerative Disease Treatment Sales Value by Application (%), 2023 VS 2030
Figure 57. Southeast Asia Rare Neurodegenerative Disease Treatment Sales Value, (2019-2030) & (US$ Million)
Figure 58. Southeast Asia Rare Neurodegenerative Disease Treatment Sales Value by Type (%), 2023 VS 2030
Figure 59. Southeast Asia Rare Neurodegenerative Disease Treatment Sales Value by Application (%), 2023 VS 2030
Figure 60. India Rare Neurodegenerative Disease Treatment Sales Value, (2019-2030) & (US$ Million)
Figure 61. India Rare Neurodegenerative Disease Treatment Sales Value by Type (%), 2023 VS 2030
Figure 62. India Rare Neurodegenerative Disease Treatment Sales Value by Application (%), 2023 VS 2030
Figure 63. Rare Neurodegenerative Disease Treatment Industrial Chain
Figure 64. Rare Neurodegenerative Disease Treatment Manufacturing Cost Structure
Figure 65. Channels of Distribution (Direct Sales, and Distribution)
Figure 66. Bottom-up and Top-down Approaches for This Report
Figure 67. Data Triangulation
Figure 68. Key Executives Interviewed
